Medpace Holdings, Inc. (NASDAQ: MEDP), a leading global provider of clinical research services, reported strong third-quarter 2024 financial results on Friday, but the company's stock plunged in after-hours trading.
For the quarter ended September 30, 2024, Medpace posted revenue of $533.3 million, an 8.3% increase from the same period last year. However, this figure narrowly missed analysts' consensus estimate of $540.5 million.
On the profitability front, the company reported net income of $96.4 million, or $3.01 per diluted share, representing a significant 36.7% year-over-year increase. This exceeded Wall Street's expectations of $2.77 per share.
Medpace's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) for the third quarter rose 31.7% to $118.8 million, with an EBITDA margin of 22.3%, reflecting improved operational efficiency and cost management.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。